Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma Feb 7, 2018
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers Jan 29, 2018
Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference Jan 22, 2018
Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131 Dec 6, 2017